SLU-PP-332
← Back to LibraryOverview
Route(s): Subcutaneous, Oral
Typical vial sizes: 10, 30 mg
Dosing window: Morning / Pre-Workout
Receptor / target: ERR Agonist
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1.0mg to 2.0mg daily | Administered in the morning or pre-workout. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative Titration 1 - 60mg Week Max Oral Tabs
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20mg am pre-workout or 7am | |
| Week 2 | 20mg am pre-workout, 20mg 11am | |
| Weeks 3-8 | 40mg am pre-workout, 20mg 11am, 20mg 2pm |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 2 - 80mg Week Max Oral Tabs
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20mg am pre-workout or 7am | |
| Week 2 | 20mg am pre-workout, 20mg 11am | |
| Weeks 3 | 40mg am pre-workout, 20mg 11am | |
| Weeks 4-8 | 40mg am pre-workout, 20mg 11am, 20mg 2pm |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 3 - 100mg week Max Oral Tabs
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20mg am pre-workout or 7am | |
| Week 2 | 20mg am pre-workout, 20mg 11am | |
| Weeks 3 | 40mg am pre-workout, 20mg 11am | |
| Weeks 4-5 | 40mg am pre-workout, 20mg 11am, 20mg 2pm | |
| Weeks 6-8 | 60mg am pre-workout, 20mg 11am, 20mg 2pm |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active malignancy: ERRα is overexpressed in multiple cancers including breast, ovarian, and prostate cancer where it promotes tumor survival, metastasis, and OXPHOS upregulation that supports tumor bioenergetics; SLU-PP-332's ERR agonism could activate these same pro-tumor transcriptional programs.
- Hormone-sensitive cancers (breast, ovarian, prostate, endometrial): while ERRs are mechanistically distinct from estrogen receptors, they share pathway convergence in hormone-sensitive tissues and have documented roles in driving progression of these cancers.
- Pregnancy: ERR nuclear receptors are involved in trophoblast development and placental energy metabolism; exogenous ERR agonism during pregnancy is not established as safe.
- Breastfeeding: no safety data established.
- Known hypersensitivity to SLU-PP-332 or related quinazolinone compounds.
- Severe cardiac arrhythmia or decompensated heart failure: ERRα is highly expressed in cardiac tissue and drives the cardiac OXPHOS gene program; in decompensated heart failure where cardiac energy metabolism is already dysregulated, supraphysiological ERR agonism may produce uncharacterized and potentially adverse effects.
- Pediatric use: ERR receptors are involved in developmental biology; safety in children is not established.
- Concurrent use with other PGC-1α or ERR-modulating agents: the magnitude of overlapping mitochondrial biogenesis stimulation from multiple simultaneous pathway activators is not characterized.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Mild lethargy post-dose during initiation: the metabolic reprogramming demands cellular resources during the gene expression transition phase; most pronounced in weeks 1-2 as new mitochondrial proteins are being synthesized; resolves as the oxidative capacity becomes established.
- Injection site irritation: redness, soreness, minor swelling at subcutaneous administration site; standard response.
- Insomnia or sleep disruption: ERR agonism and mitochondrial biogenesis drive upregulated metabolic rate; dosing in the afternoon or evening may produce difficulty falling asleep; morning and pre-workout dosing protocols exist specifically to prevent this.
- GI discomfort with oral tablet formulations: nausea, abdominal bloating, or loose stools at higher oral doses; the split oral dosing schedules (morning, 11am, 2pm) distribute the load to reduce peak GI exposure.
- Potential cardiovascular effects: ERRα's cardiac expression means SLU-PP-332 has cardiac metabolic activity; in healthy subjects this is likely beneficial but cardiac effects in diseased tissue are not characterized.
- Theoretical ERR-mediated cancer cell activation: the most significant theoretical adverse concern; the same transcriptional programs SLU-PP-332 activates for metabolic benefit in healthy tissue overlap with pro-tumor ERRα programs in oncological contexts.
- Unknown long-term adverse effects: no published Phase 1 human clinical trial data exists as of mid-2026; the complete human adverse event profile is genuinely uncharacterized beyond animal studies and early research observation.
- No estrogenic side effects: despite the "estrogen-related" nomenclature, SLU-PP-332 does not activate ERα or ERβ estrogen receptors and produces no estrogenic effects (gynecomastia, feminization, HPTA suppression).
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.